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The field of infectious diseases currently takes a reactive approach and treats infections as they present in patients. Although certain 
populations are known to be at greater risk of developing infection (eg, immunocompromised), we lack a systems approach to de-
fine the true risk of future infection for a patient. Guided by impressive gains in “omics” technologies, future strategies to infectious 
diseases should take a precision approach to infection through identification of patients at intermediate and high-risk of infection 
and deploy targeted preventative measures (ie, prophylaxis). The advances of high-throughput immune profiling by multiomics ap-
proaches (ie, transcriptomics, epigenomics, metabolomics, proteomics) hold the promise to identify patients at increased risk of in-
fection and enable risk-stratifying approaches to be applied in the clinic. Integration of patient-specific data using machine learning 
improves the effectiveness of prediction, providing the necessary technologies needed to propel the field of infectious diseases med-
icine into the era of personalized medicine.
Keywords.  high-throughput technologies; infectious diseases; invasive fungal infections; systems immunology.
Infectious diseases (ID) physicians currently take a reactive ap-
proach in which we provide diagnostic and therapeutic advice on 
patients with established infection. For example, Staphylococcus 
aureus bacteremia is commonly encountered in inpatient set-
tings. Although S aureus colonization and unsterile techniques 
contribute to incidents of infection, there is clearly a role for 
host factors in modulation of potential infection and disease 
severity. The most common conditions that portend increased 
risk for S aureus bacteremia are diabetes, intravenous drug use, 
presence of central lines in patients requiring dialysis, cancer 
chemotherapy, and corticosteroid use [1]. The underlying as-
sumption is that bacteremia in this patient population cannot 
be accurately predicted, and therapeutic approaches are purely 
reactive—treatment begins once the infection is established and 
subsequently diagnosed. Unfortunately, this approach permits 
widespread host damage from metastatic infection. Mortality 
rates of 20%–40% have not changed in the past several dec-
ades, indicating that another approach is required [1]. The goal 
for the field of ID in the 21st century should be to predict and 
prevent infections in individual patients before they occur by 
interrogating the patients’ immune system using multiomics 
approaches. We have focused this review on the human immu-
nology because the pathogen virulence and its impact has been 
discussed elsewhere [2–4].
The need for a preemptive, risk-modifying approach to in-
fections in ID is evident by the increasing number of high-risk 
individuals due to advances in immunosuppression enabling 
solid organ transplantation, chemotherapy for cancer, and 
immunomodulatory therapeutics for autoimmune diseases 
[5–9]. Evidence-based prophylaxis has reduced ID burden in 
immune compromised patient (eg, Pneumocystis jirovecii pneu-
monia prophylaxis in human immunodeficiency virus [HIV] 
patients with CD4 count of <200 cells/µL) [10]. However, total 
T-cell counts do not account for specific effector T-cell popu-
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future of ID medicine should predict and prevent infection 
to avoid severe outcomes (eg, delay of therapy for underlying 
processes and death). As a field, we are poised to leverage our 
understanding of basic mechanisms in microbiology and im-
munology to learn how to risk-stratify patients and judiciously 
deploy prophylactic antimicrobials to prevent infections using a 
personalized medicine approach. In the near term, multiomics 
studies can nominate specific molecular and cellular biomarkers 
that can be measure using platforms currently deployed in pa-
tient care that will inform clinical decisions.
Medical mycology would greatly benefit from a precision ap-
proach to infection. Invasive fungal infections (IFIs) are dreaded 
complications in immunocompromised populations, often car-
rying morality rates exceeding 50% [7, 11, 12]. Clinical data and 
current literature implicate certain components of the immune 
system as critical for swift clearance of fungal pathogens [13–
15]. However, the rules governing an inflammatory response 
that contributes to the broad spectrum of clinical outcomes in 
immunocompromised patients are not known. For example, in-
dividuals that receive a single- or double-lung transplant due 
to end-stage pulmonary disease are at high-risk of developing 
and succumbing to IFIs. The opportunistic fungal pathogen 
Aspergillus fumigatus is the most commonly diagnosed fungal 
pathogen in lung transplant recipients (LTRs), with lower inci-
dence of infection by Mucor, Cryptococcus, and endemic fungi 
(Histoplasma, Blastomyces, Coccidioides) [16, 17]. Furthermore, 
A fumigatus colonization in these patients is associated with 
accelerated chronic rejection [18, 19]. Understanding the un-
derlying factors that predict development of fungal infection 
in LTRs, and consequent rejection, will enable targeted preven-
tative strategies (eg, vaccine, prophylactics, and/or alteration 
in immunosuppression) in those at the greatest risk of poor 
outcome.
Application of precision ID approaches benefits not only rel-
atively small, highly defined cohorts (~4000 lung transplants 
annually), but also larger, more heterogenous at-risk popula-
tions. Risk of infection in healthcare settings is amplified by the 
need for invasive procedures (eg, insertion of central venous 
catheters) leading to a break in the skin barrier and disruption 
of commensal fungal populations [20, 21]. Candida spp is the 
seventh most prominent pathogen in healthcare-associated in-
fection ([HAI] <10% of all pathogens) and is a leading cause of 
bloodstream infection (~22% of all pathogens) [22]. The obser-
vation that only a subset of at-risk patients develop candidemia 
despite ubiquitous exposure indicates that host factors potently 
modulate risk for this infection. Precision ID enables identi-
fication of patients at the highest risk of developing invasive 
candidiasis so that a targeted prophylaxis approach will lead 
to less morbidity and improved outcomes. It is not hard to im-
agine the benefits of a screen to identify hospitalized patients 
at-risk of not only Candida infection, but also common bac-
terial pathogens contributing to HAIs (eg, Clostridium difficile, 
S aureus, Pseudomonas aeruginosa) [22]. Although the idea of 
personalized medicine is not new [23–26], technologies and bi-
oinformatic approaches required to advance precision ID are 
becoming available, and they are broadly applied to other fields 
of medicine (eg, oncology).
POTENTIAL APPLICATION OF NEXT-GENERATION 
TECHNOLOGIES IN THE CLINICAL SETTING
The immune system, one of the most complex and dynamic 
biological systems in mammals, comprises diverse cell types 
with varying functional states. Advances in high-throughput 
profiling technologies, particularly single-cell omics platforms, 
enable comprehensive characterization of immune components 
at multiple scales. However, immunity is not merely a sum of its 
components, and its behavior cannot be explained or predicted 
solely by examining individual components. Therefore, sys-
tems biology approaches are essential for decoding the cellular 
complexity, plasticity, and functional diversity of the immune 
system. The emerging field of systems immunology enables 
physician-scientists to better understand how the immune 
system works in health and disease. Evaluation of clinical sam-
ples from known high-risk populations will empower future 
risk-stratification of these populations and improve our ability 
to deliver precision ID care. In addition, there is increasing ev-
idence that local immunity provides a better window into im-
mune responses than interrogating peripheral blood alone [27]. 
Interrogation of tissue resident memory cells has provided 
significant insight into host responses and autoimmune dis-
eases [28, 29]. Specifically, group 3 innate lymphoid cells and 
T helper type 17 (Th17) cells may serve as key components of 
tissue-resident memory cells acquired over time or elicited by 
mucosal immunization that provides the host with enhanced 
immunity against specific pathogens [30]. For example, LTRs 
are often diagnosed with pulmonary infection, and therefore it 
is critical to interrogate both systemic (ie, peripheral blood) and 
local (ie, bronchoalveolar lavage fluid and lung biopsies) patient 
samples to provide a fuller picture of immunity in response to 
infection. Understanding local and systemic immune response 
to infection at such a large-scale will enable refinement of fu-
ture clinical assays and identification of relevant biomarkers 
in susceptible patient populations. We envision an even closer 
relationship between the ID/transplant physicians and oncolo-
gists/rheumatologists whereby ID physicians assists the treating 
physician to select appropriate preventative strategies to avoid 
life-threatening infections in at-risk patients.
Transcriptional Genomics
Development of systematic transcriptomic profiling and com-
putational analyses have provided meaningful translational in-
sights into various disease states and immunological response in 
infections [31–37]. In the immune system, cell populations may 
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of ribonucleic acid (scRNA-seq) or examination of epigenetic 
modifications can reveal cell-to-cell variability that may help 
subpopulations of cells to rapidly adapt to evolving environ-
ments. Single-cell omics approaches, which result in quantita-
tive and high-resolution snapshots of thousands to millions of 
cells, interrogate human systems and underlying phenotypes 
that may contribute to disease. Although it is less expensive, 
bulk RNA-sequencing remains a lower powered approach be-
cause results generated reflect an average of all cells, which may 
lead to critical changes in rare cell populations being overlooked. 
The scRNA-seq analysis provides an unbiased, data-driven 
way to systematically detect cellular states to reveal diverse si-
multaneous facets of cellular identity, from discrete cell types 
to continuous dynamic transitions, which cannot be defined 
by a handful of predefined markers or for which markers are 
not yet known (Figure 1A). For example, scRNA-seq identified 
rare epithelial cells, ionocytes, as the major source of cystic fi-
brosis transmembrane conductance regulator, which reshaped 
the cystic fibrosis field [38]. In addition, a recent study dem-
onstrated a monocyte phenotype, termed MS1, associated with 
bacterial sepsis, which appears to be a hallmark of severe infec-
tions [39]. In previous studies, after the MS1 marker genes were 
defined from scRNA-seq, there was evidence of its presence 
in dozens of bulk transcriptional studies of sepsis with diverse 
anatomic sources and microbiological causes, underscoring the 
power of this approach.
Methodological adaptations such as T-cell receptor (TCR) or 
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Figure 1. Workflow of transcriptional genomics from patient samples through single-cell ribonucleic acid sequencing (scRNA-seq) (A) and spatially resolved transcriptomics 
(B). (A) Samples for scRNA-seq require dissociation of cells to ensure cells are not clumped together. Cells are sorted via antibody labeling to sort immune cells and 
nonimmune cells. Samples undergo reverse transcription and complementary deoxyribonucleic acid amplification and profiled by sequencing through selected sequencing 
technologies. These libraries often achieve 50 000 reads, providing detailed readouts of cell populations and substates, T-cell receptor (TCR) and B-cell receptor (BCR) 
profiling, and underlying immune pathways in disease correlating with disease. (B) Tissue samples from infected regions, in this example lung tissue from lung transplant 
recipients infected with Aspergillus, are snap frozen and sectioned into thin slices for spatial transcriptomics. After permeabilization, tissues are exposed to probes designed 
to target specific RNA sequences followed by amplification that enables visualization of transcripts. Although methodology differs depending on the approach used, the 
current example of these probes requires a ligation and crosslinking with a fluorescent tag. The resulting data allow analysis of transcripts in their spatial location. BAL, 
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of transcriptomes and epitopes by sequencing (CITE-seq) fur-
ther increase the power of scRNA-seq. T-cell responses are es-
sential to adaptive immunity to pathogens, including in IFIs. 
For example, investigations in patients with HIV demonstrate 
that a loss of T-cell immunity is closely tied to incidence of 
cryptococcal meningitis [40–42]. Impaired T-cell responsive-
ness in other immunologically vulnerable populations have also 
been observed in invasive Aspergillus and Candida infections 
[43, 44]. In addition, the importance of B cells in ID has been 
well documented in viral and bacterial infections, including 
severe acute respiratory syndrome coronavirus 2, Klebsiella, 
and Haemophilus influenzae [45–48]. The RNA-seq paired 
with TCR or BCR repertoire analyses enables investigators to 
interrogate expansion of T- and B-cell populations in disease. 
In addition to these paired receptor analyses, CITE-seq, which 
has been implemented in large-scale translational human im-
munology projects, enables simultaneous single-cell measure-
ments of a predefined array of surface proteins and unbiased 
gene expression [49]. The CITE-seq utilizes oligonucleotide 
barcoded antibodies to quantitate protein expression through 
flow cytometry measurements in tandem with messenger RNA 
information provided my RNA-seq. Coupled with scRNA-seq, 
these paired analyses provide a comprehensive look at immune 
cells and tissues in disease.
Although scRNA-seq provides ample information about the 
transcriptome in different cell populations, there is a loss of spa-
tial data due to the required step of tissue dissociation. Through 
advances in sequencing and imaging technologies, under-
standing expression of transcripts at the single-cell level in their 
spatial layout provides better understanding within the distinct 
microenvironment in infected regions and tissues (Figure 1B). 
Numerous novel spatial transcriptomics approaches have been 
reviewed previously [37, 50]. Additional complementary ap-
proaches such as multiplexed cytometric imaging (CODEX) 
and in situ hybridization (RNAscope) may be used to improve 
power of spatial transcriptomics [37, 51, 52]. A key advantage 
to spatial transcriptomics is the ability to determine the impact 
of local immune response in tissue, with temporal resolution. In 
infection, development of a granuloma occurs during infection 
to contain pathogens. Use of spatial transcriptomics of these 
granulomas may provide insight into the molecular and cellular 
mechanisms that govern pathogen containment. Thus, com-
plementary scRNA-seq and spatial transcriptomics approaches 
may provide ample information on host-pathogen responses 
during infections and insights into prognosis.
Epigenomics
Although studies investigating genetic susceptibilities have 
identified polymorphisms associated with infection (eg, 
CARD9 mutations in IFIs), translation to the clinic does not 
provide the whole story for risk and development of infec-
tion [53]. Common genetic traits do not produce consistent 
phenotype, but epigenetic modifications may bridge the gap 
between phenotype and genes. Epigenetic modifications 
alter gene expression and function through deoxyribonucleic 
acid methylation and histone modification (eg, acetylation, 
methylation, phosphorylation) [54]. Methodology to inter-
rogate epigenomic changes utilize chromatin conformation 
studies (eg, assay for transposase-accessible chromatin using 
sequencing [ATAC-seq]) and histone modification profiling 
(eg, chromatin immunoprecipitation) of clinical samples 
(Figure 2) [55, 56]. Longitudinal studies that examine epige-
netic modifications paired with scRNA-seq in high-risk pa-
tients may provide a roadmap to infection susceptibility and 
ability to effectively clear pathogens. Epigenetic-based treat-
ments are being explored in the context of HIV infections, 
leading to preclinical and clinical trials for combination antire-
troviral therapy [57, 58].
Historically, immune memory has been considered a func-
tion of the adaptive immune system (eg, T cells and B cells), 
providing highly specific, long-lasting protection against in-
vaders. Trained immunity is the concept of long-term func-
tional reprogramming (namely, through epigenetic processes) 
in early immune responders, also known as innate immune cells 
(eg, neutrophils, monocytes, dendritic cells) [59]. Interaction 
with these innate cells and a pathogen leads to altered response 
during a second challenge with the same pathogen, contrib-
uting to innate-mediated short-term (ranging from 3 months to 
1 year) protection against foreign invaders [59]. Histone meth-
ylation or acetylation are hallmarks of trained immunity in in-
nate immune cells after stimulation with the fungal cell wall 
carbohydrate β-1,3-glucan, a major component of Candida spp 
[60–62]. Expansion of these studies into individuals with an ele-
vated risk of infection may provide insights into novel preventa-
tive and therapeutic strategies to preemptively treat infections.
Metabolite Profiling
Metabolomics systematically quantifies metabolites in bi-
ological samples. These metabolites are derived from met-
abolic processes as well as complex biological interactions 
within an organism. Clinical metabolomics detects the di-
rect result generated by a biochemical response to a variety 
of factors, including invading pathogens. The benefit of me-
tabolite profiling is well demonstrated in the fields of cardi-
ovascular disease, kidney disease, cancer metabolism, and 
emerging in the field of ID [63–71]. Identification of circu-
lating metabolites offers biomarker profiles that precede dis-
ease and track severity of disease. Technology platforms for 
metabolic profiling typically utilize mass spectrometry (MS) 
coupled with chromatographic separation (including liquid 
chromatography and gas chromatography) and/or nuclear 
magnetic resonance spectroscopy (NMR) [72, 73]. Because 
there is ample diversity of metabolites, priority should be 
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Liquid chromatography-MS, which has emerged as the work-
horse for large-scale metabolomics, enables quantification 
of a broad range of metabolites including lipids, sugars, or-
ganic acids, amino acids, amines, nucleotides, bile acids, and 
acylcarnitines based on the detection method used (Figure 3). 
Although there are hundreds of known compounds through 
reference libraries, follow-up protocols (including NMR and 
other MS approaches) are necessary to identify thousands of 
unknown peaks. One barrier to keep in mind with respect 
to comprehensive metabolomic profiling is the dynamic na-
ture of metabolism and metabolite signatures, which requires 
immediate processing to accurately dissect patient profiles. 
Furthermore, an advantage of metabolomics is the ability to 
identify metabolites from small sample volumes (as little as 
10 µL), contributing to the potential to provide early clinical 
measurements leading to preventative strategies and treat-
ments of disease.
It has become evident that immune cells rely on changes in 
cellular metabolism to mount effective antimicrobial responses, 
with glucose metabolism being a central player in immune cell 
function, although data from actively infected human patients 
remain limited [74]. In recent studies, researchers have demon-
strated the role of metabolism in trained immunity to fungal 
pathogens. Emerging data suggest that an increase in glycol-
ysis and glutaminolysis used in the tricarboxylic acid cycle and 
a corresponding decrease in oxidative phosphorylation are 
important to the host defense against fungal pathogens [60, 
75–77]. It is unfortunate that these studies primarily utilize ex 
vivo stimulation of peripheral blood samples from healthy in-





















Figure 2. Epigenomic approaches utilizing clinical local (eg, lung tissue and bronchoalveolar lavage [BAL]) and systemic (eg, blood) samples. (A) Assay for transposase-
accessible chromatin using sequencing (ATAC-seq) measures chromatin conformation differences. The hyperactive transposase Tn5 loaded with a next-generation sequencing 
library enables fragmentation of open chromatin regions. These fragments are amplified and sequenced to provide physician-scientists with accessible chromatin regions 
at the single-cell level. (B) Histone modifications profiling through chromatin immunoprecipitation (ChIP) is an antibody-based technology that selectively enriches deoxyri-
bonucleic acid (DNA)-binding proteins and their respective DNA targets (eg, histone modifications by methylation or acetylation). The DNA and its associated proteins on 
the chromatin are first crosslinked followed by fragmentation by sonication or a nuclease digestion. These fragments are then immunoprecipitated via antibody selection, 
which removes remaining cellular debris. Although there are multiple downstream analyses that can be run on ChIP precipitates, sequencing after DNA purification provides 
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in high-risk patient populations is warranted. In limited studies 
into metabolic changes in organ transplantation, researchers 
identified an increase in glycolysis during transplant rejection, 
which provides rapid adenosine triphosphate generation and 
biosynthetic intermediates that support anabolic processes [78, 
79]. Expansion of these data in primary clinical samples (both 
systemic and locally) will provide novel monitoring strategies 
for LTRs for rejection and development of IFIs.
Considerations for timing of clinical sample collection, partic-
ularly in ID medicine, is critical and further studies are needed. 
In sepsis, metabolism rapidly changes throughout progression 
of disease. Metabolic profiles differentiated patients who devel-
oped sepsis in adults admitted to the intensive care unit due to 
traumatic injury [80]. Thus, these profiles could be applied to 
precision medicine approaches to identify patients most likely 
to develop infection. Understanding longitudinal changes in 
infection would enable clinicians to better predict the course 
of disease. Furthermore, examination of the metabolome may 
be applied to predict drug response. Investigation into novel 
therapeutics and treatment strategies is essential with the emer-
gence of more multidrug-resistant pathogens. Metabolomics 
could be applied as an indicator for the pathogen, which cur-
rently relies on culture methods. A study of fungal infections in 
neonates identified elevations of the amino acid, serine, during 
active infection, which declined after antifungal therapy, when 
compared with healthy controls [81]. Thus, large-scale metab-
olomics to identify diagnostic biomarkers, monitor progress of 
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Figure 3. Metabolite profiling through nontargeted approaches of known and unknown peaks. Patient samples for metabolomics require quick processing to extract me-
tabolites prior to them being changed by biological mechanisms. Because the metabolome consists of molecules with very different physical properties, for example, both 
cationic and anionic compounds ranging from very polar to very nonpolar, it is necessary to devise distinct sample preparation and liquid chromatography-mass spectrometry 
(LC/MS) procedures to optimize metabolite coverage. These methods utilize different settings for separation via gas (gas chromatography [GC]) or LC step. Mass spectrom-
etry analysis in the positive (C8-pos or hydrophilic interaction chromatography [HILIC]-pos) or negative (C18-neg or HILIC-neg) ion mode provides a wide array of metabolic 
peaks. These peaks can be compared with known metabolite library for identification. In addition to matches to known metabolites, there are often thousands of unknown 
peaks, which requires rigorous methodology to identify and authenticate metabolites. Identification and authentication approaches rely on tandem mass spectrometry (MS/
MS)-based structure prediction as well as compound isolation and subsequent processing through GC or nuclear magnetic resonance spectroscopy (NMR) methodologies. 
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Proteomic Analyses
The proteome encompasses the overall protein content within a 
cell, including protein-protein interactions and posttranslational 
modifications (eg, phosphorylation) at a particular time point. 
Measurements of global protein expression within cells or tissues 
encompass a variety of approaches ranging from targeted, high-
dimensional panels to large-scale, unbiased techniques. Protein 
phosphorylation is an essential posttranslational modification 
that enables regulation of most biological processes [82–86]. In 
one sense, the recipe for a successful immune response to an 
invading pathogen is timely activation and inhibition of distinct 
signaling pathways in immune cells to provide efficient antimicro-
bial effect without inducing excessive tissue damage. Correlating 
these changes by monitoring phosphorylation status of key in-
tracellular signaling molecules with clinical outcome may pro-
vide critical insights into the mechanism of protective immunity. 
Mass cytometry-based (ie, cytometry by time of flight [CyTOF]) 
phosphoproteomics methodology provides a platform to glob-
ally study activation or inhibition of multiple signaling pathways 
across the entire immune system with single-cell resolution [87]. 
Indeed, novel insights into TLR signaling and T-cell activation 
have been uncovered by phosphoproteomics analysis (Figure 4A) 
Short stimulation












































Figure 4. Workflow for mass cytometry (A), multianalyte array (B), and aptamer-based assay (C) proteomic approaches utilizing human patient samples. (A) To interrogate ac-
tivated and inhibited pathways through phosphoproteomics, biological samples are briefly (15 minutes to 6 hours) stimulated with pathogen (eg, Aspergillus) of interest as well 
as with proper controls (eg, unstimulated and lipopolysaccharide). Stimulated samples are then incubated with metal-labeled antibodies targeting immune cells (cell surface 
antibodies), intracellular signaling proteins (phosphor-specific antibodies), and/or cytokines (intracellular cytokine antibodies). Cytometry by time-of-flight mass spectrometry 
(CyTOF) merges traditional flow cytometry with inductively coupled mass spectrometry to assess more than 50 simultaneously measured parameters on a cell-by-cell basis. (B) 
Targeted multianalyte arrays enable measurement of multiple proteins within a 96- or 384-well plate. Cell supernatants are put in individual wells containing color-coded beads 
precoated with antibodies for multiple analytes of interest. Detection antibodies for each target analyte as well as streptavidin-phycoerythrin (PE) are added for biotinylated 
detection. Detection and quantification of each analyte can be determined using a flow-based instrument or magnetic beads. Panels can be created to target specific secreted 
proteins. (C) Aptamer-based proteomics enables aptamers (eg, Slow Off-rate Modified Aptamers [SOMAmers]) labeled with a fluorophore, photocleavable linker, and biotin 
to be immobilized on streptavidin-coated beads and incubated with patient samples. After a biotin-tagging step, these aptamer-protein complexes are released by ultraviolet 
(UV) light-mediated photocleavage of the linker. The biotin labeled- aptamer-protein complexes are captured by a second set of streptavidin-coated beads and aptamers are re-
leased after incubation with denaturing buffer. A microarray chip is used to quantify fluorescence intensity within to total protein amount of the initial sample. Throughout this 
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[88, 89]. Insights into the distribution and activation or inhibition 
of intracellular signaling pathways by targeting phosphorylation 
states of known signaling molecules in immune cells provides 
mechanistic understanding of disease states and infection [85]. 
Targeted profiling via the CyTOF platform enables investigators to 
tailor a panel of ~50 markers to dissect specific cell subsets and ac-
tivation states of different proteins. For example, the CyTOF panel 
examining differences in innate immunity from invasive candidi-
asis HAI may include proteins associated with Candida immunity, 
such as iNOS, Arg1, Ym1, Ym2, IL-4, and Egr2 [90–92].
Secretion of proteins to the external environment is critical 
in maintaining cell-cell communication and recruitment of 
immune cells in response to pathogens. These secreted pro-
teins include hormones, cytokines, chemokines, and growth 
factors. Measurement of these secreted proteins (secretome) 
can be done through a targeted multiplex array approach (eg, 
multianalyte assay). Multiplex assays allow for simultaneous 
detection and quantification of multiple proteins (Figure 4B). 
Stimulation of peripheral blood mononuclear cells (PBMCs) 
or tissues from patients with a pathogen may provide insights 
in the variations of the secretome in patients with high-risk of 
infection compared with healthy controls. Multianalyte assays 
have been used to investigate numerous infections [93–96].
Although a targeted approach may provide single-cell reso-
lution and insights into known immune factors, application of 
large-scale, unbiased proteomic approaches contributes to iden-
tification of novel proteins associated with disease. Furthermore, 
this type of approach may identify biomarkers of disease and 
clinical severity. The SomaScan assay developed by SomaLogic 
is an aptamer-based approach that measures up to 7000 unique 
human proteins (Figure 4C). Although it is optimized for a set 
of core sample types (plasma, serum, urine), the SomaScan assay 
sample source has the ability to interrogate noncore sample 
sources (bronchoalveolar lavage, cell-conditioned media, ce-
rebrospinal fluid, exosomes, sputum, tissue homogenates). 
Aptamer-based proteomics is widely used in neurodegenera-
tive disease, cardiovascular diseases, and infections [97–100]. 
Indeed, use of Slow Off-rate Modified Aptamers (SOMAmers) 
in the SomaScan assay and RNA-seq was used to identify tissue-
specific clinical markers of heart, kidney, liver, and skeletal muscle 
damage in patients with coronavirus disease 2019 (COVID-19) 
[101]. These biomarkers can be used upon presentation to the 
hospital using blood samples to detect COVID-19-driven organ 
damage. Taken together, these proteomic approaches identify 
activated pathways and biomarkers of infection critical for im-
plementation of precision ID medicine into clinical practice.
PRECISION MEDICINE IN INFECTIOUS DISEASES
Transcriptional expression, epigenetic forms, metabolites, and 
protein expression are all interwoven to directly impact im-
mune responses in disease. Individually, high-throughput 
omics approaches provide a window into immune responses 
and phenotypes that portend increased risk of infection and 
may foretell clinical course. Given the complex interplay among 
different aspects of the immune system, combining multiomics 
modalities into a computational framework increases predic-
tive power and reveals crosstalk between different layers of bi-
ological profiling (Figure 5). However, merging transcriptomic, 
epigenomic, metabolomic, and proteomic features into predic-
tive models will require continued development of new statis-
tical tools designed to study high-dimensional datasets. Recent 
advances in bioinformatic processes overcome many ana-
lytic challenges that previously prevented the development of 
models to accurately predict patient outcomes [86, 102, 103]. 
Regularized regression methods such as the Elastic Net algo-
rithm have proven useful for selection of key predictive features 
and development of clinical models [104]. A stacked general-
ization method that combines multiple regularized regression 
models developed from individual omic datasets has also been 
recognized as a valuable approach for data integration and can 
improve overall model performance [86]. This approach has 
been successfully implemented for the prediction of various 
clinical outcomes, including development of insulin resist-
ance [105], onset of spontaneous labor [106], survival of per-
sons with pancreatic cancer [107], and severity of COVID-19 
infections [85]. Furthermore, development of effective visual-
ization methods for these integrated machine learning models 
improves understanding of results [108, 109]. Taken together, 
these analytic approaches provide mechanistic information re-
garding the crosstalk between various biological systems that 
could not otherwise be identified from each assay individually.
Implementation of precision ID medicine requires immune 
profiling of well phenotyped human cohorts, particularly pa-
tients with known risk factors (eg, solid organ transplantation, 
cancer, invasive procedures). Although recent advances have 
improved cost effectiveness and availability of these omics tech-
nologies, there is still a heavy burden on resources. To realize the 
full potential of these technologies, there needs to be significant 
reduction in cost of processing and analyzing each sample to 
ensure access to all patients. Major funding agencies acknowl-
edge this need as demonstrated by new funding mechanisms 
through the National Institutes of Health (Human Immunology 
Project Consortium) and European Research Council (Horizon 
Program) [110, 111]. Further multiomics studies are warranted 
to make precision ID a clinical reality.
CONCLUSIONS
Translational systems immunology provides the framework 
to shift from reactive to proactive precision ID medicine, 
improving the quality of life and dampening complications 
in high-risk populations (Figure 5). Although many omics 
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Figure 5. Workflow of reactive (A) and precision (B) infectious diseases (ID) medicine. A precision approach would enable clinicians to use preventative strategies, leading to 
fewer infections and infectious complications, including targeted prophylaxis or therapies that enhance immunity to specific pathogens. (C) Incorporation of multiomics approaches 
into an integrative machine learning model more accurately predicts clinical outcomes. Multiomics include transcriptomics (bulk or single-cell ribonucleic acid [RNA] sequencing 
[with or without paired analyses] and spatial transcriptomics), epigenomics (chromatin immunoprecipitation [ChIP] and assay for transposase-accessible chromatin using sequencing 
[ATAC-seq]), metabolomics (liquid chromatography tandem mass spectrometry [LC-MS] and one-dimensional proton nuclear magnetic resonance spectroscopy [NMR]), and prote-
omics (cytometry by time-of-flight [CyTOF], aptamer-based methods [SomaScan], and multianalyte array). Combining these multiomics methodologies across longitudinal samples of 






/ofid/article/8/11/ofab483/6375269 by 81392966 user on 07 D
ecem
ber 2021
10 • OFID • Ward et al
pathogens, barriers remain that need to be addressed. One 
major barrier to our understanding is the reliance on an-
imal models to study human disease, because these often 
do not recapitulate the complexity of disease. Furthermore, 
many reports using these omics approaches utilize samples 
from healthy patients exposed ex vivo to pathogens. In pre-
vious studies, researchers have attempted to understand ini-
tial immune responses in C albicans-stimulated PBMCs using 
RNA-seq, and they unveiled the predominance of interferon 
responses and activation of major innate cell populations 
(eg, neutrophils, macrophages, monocytes). Although the as-
sumptions are foundational, the generalizability of these ex 
vivo stimulations of blood from normal volunteers is limited. 
In addition, single-cell resolution permits identification of the 
precise cell types driving observed transcriptional changes, 
thus suggesting candidate immune pathways/circuits for pre-
cision diagnostics and therapeutic targeting. Thus, there is a 
need for multiomics investigations using well defined clinical 
cohorts at greater risk of infections. Integration of these data 
will result in the necessary information to apply risk stratifica-
tion to high-risk populations, preventive strategies to reduce 
the burden of infection, and allow for targeted rather than 
prophylactic antibiotic strategies.
Acknowledgments
We thank Nicole Wolf for assistance with the artwork (illustrations for 
Figures 1–5).
Financial support. This study was funded by the National Institutes 
of Health, Grant Numbers R01AI136529 and R01AI150181 (to J. M. V.), 
K08HL122528 and R01HL157414 (to J. L. H.), R35GM138353 (to N. A.), 
R35GM137936 and 1P01HD106414 (to B. G.), and R01AI132638 to M. K. M.
Potential conflicts of interest. All authors: No reported conflicts of in-
terest. All authors have submitted the ICMJE Form for Disclosure of 
Potential Conflicts of Interest. 
References
 1. Souli M, Ruffin F, Choi SH, et al. Changing characteristics of Staphylococcus 
aureus bacteremia: results from a 21-year, prospective, longitudinal study. Clin 
Infect Dis 2019; 69:1868–77.
 2. Lee MH, Nuccio SP, Raffatellu M. Pathogen interference: targeting virulence fac-
tors to tackle intracellular microbes. Cell Chem Biol 2020; 27:765–7.
 3. Jack RS. Evolution of immunity and pathogens. Results Probl Cell Differ 2015; 
57:1–20.
 4. Chin VK, Lee TY, Rusliza B, Chong PP. Dissecting Candida albicans infection 
from the perspective of C. albicans virulence and omics approaches on host-
pathogen interaction: a review. Int J Mol Sci 2016; 17:1643
 5. Baddley JW, Cantini F, Goletti D, et al. ESCMID study group for infections in 
compromised hosts (ESGICH) consensus document on the safety of targeted and 
biological therapies: an infectious diseases perspective (soluble immune effector 
molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect 2018; 
24:10–20.
 6. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal coinfection in in-
dividuals with coronavirus: a rapid review to support COVID-19 antimicrobial 
prescribing. Clin Infect Dis 2020; 71:2459–68.
 7. Rayens E, Norris KA, Cordero JF. Mortality trends in risk conditions and in-
vasive mycotic disease in the United States, 1999-2018. Clin Infect Dis 2021. 
doi:10.1093/cid/ciab336.
 8. Zembower TR. Epidemiology of infections in cancer patients. Cancer Treat Res 
2014; 161:43–89.
 9. Varughese T, Taur Y, Cohen N, et al. Serious infections in patients receiving 
ibrutinib for treatment of lymphoid cancer. Clin Infect Dis 2018; 67:687–92.
 10. Sidhu VK, Foisy MM, Hughes CA. Discontinuing Pneumocystis jirovecii pneu-
monia prophylaxis in HIV-infected patients with a CD4 cell count <200 cells/
mm3. Ann Pharmacother 2015; 49:1343–8.
 11. Cornely OA, Gachot B, Akan H, et al; EORTC Infectious Diseases Group. 
Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious 
Diseases Group (IDG) of the European Organization for Research and Treatment 
of Cancer (EORTC 65031). Clin Infect Dis 2015; 61:324–31.
 12. Taccone FS, Van den Abeele AM, Bulpa P, et al; AspICU Study Investigators. 
Epidemiology of invasive aspergillosis in critically ill patients: clinical presenta-
tion, underlying conditions, and outcomes. Crit Care 2015; 19:7.
 13. Romani L. Immunity to fungal infections. Nat Rev Immunol 2011; 11:275–88.
 14. Ward RA, Vyas JM. The first line of defense: effector pathways of anti-fungal in-
nate immunity. Curr Opin Microbiol 2020; 58:160–5.
 15. Köhler JR, Hube B, Puccia R, et al. Fungi that infect humans. Microbiol Spectr 
2017; 5. doi:10.1128/microbiolspec.FUNK-0014-2016.
 16. Baker AW, Maziarz EK, Arnold CJ, et al. Invasive fungal infection after lung trans-
plantation: epidemiology in the setting of antifungal prophylaxis. Clin Infect Dis 
2020; 70:30–9.
 17. Kennedy CC, Razonable RR. Fungal infections after lung transplantation. Clin 
Chest Med 2017; 38:511–20.
 18. Pasupneti S, Manouvakhova O, Nicolls MR, Hsu JL. Aspergillus-related pulmo-
nary diseases in lung transplantation. Med Mycol 2017; 55:96–102.
 19. Weigt SS, Copeland CAF, Derhovanessian A, et al. Colonization with small co-
nidia Aspergillus species is associated with bronchiolitis obliterans syndrome: a 
two-center validation study. Am J Transplant 2013; 13:919–27.
 20. Arias S, Denis O, Montesinos I, et al. Epidemiology and mortality of candidemia 
both related and unrelated to the central venous catheter: a retrospective cohort 
study. Eur J Clin Microbiol Infect Dis 2017; 36:501–7.
 21. Poissy J, Damonti L, Bignon A, et al; FUNGINOS; Allfun French Study Groups. 
Risk factors for candidemia: a prospective matched case-control study. Crit Care 
2020; 24:109.
 22. Magill SS, Edwards JR, Bamberg W, et al; Emerging Infections Program 
Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey 
Team. Multistate point-prevalence survey of health care-associated infections. N 
Engl J Med 2014; 370:1198–208.
 23. Carvalho A, Goldman GH. Editorial: an omics perspective on fungal infection: 
toward next-generation diagnosis and therapy. Front Microbiol 2017; 8:85.
 24. Moser C, Lerche CJ, Thomsen K, et al. Antibiotic therapy as personalized medi-
cine - general considerations and complicating factors. APMIS 2019; 127:361–71.
 25. van de Veerdonk FL, Gresnigt MS, Verweij PE, Netea MG. Personalized medicine 
in influenza: a bridge too far or the near future? Curr Opin Pulm Med 2017; 23: 
237–40.
 26. Al-Mozaini MA, Mansour MK. Personalized medicine. Is it time for infectious 
diseases? Saudi Med J 2016; 37:1309–11.
 27. Farber DL. Tissues, not blood, are where immune cells function. Nature 2021; 
593:506–9.
 28. Quinton LJ, Jones MR, Robson BE, Mizgerd JP. Mechanisms of the hepatic acute-
phase response during bacterial pneumonia. Infect Immun 2009; 77:2417–26.
 29. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflamma-
tion defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 
180:388–95.
 30. Iwanaga N, Kolls JK. Updates on T helper type 17 immunity in respiratory dis-
ease. Immunology 2019; 156:3–8.
 31. Sade-Feldman M, Yizhak K, Bjorgaard SL, et al. Defining T cell states associated 
with response to checkpoint immunotherapy in melanoma. Cell 2018; 175:998–
1013.e20.
 32. Villani AC, Satija R, Reynolds G, et al. Single-cell RNA-seq reveals new types 
of human blood dendritic cells, monocytes, and progenitors. Science 2017; 
356:eaah4573. 
 33. Dixit A, Parnas O, Li B, et al. Perturb-seq: dissecting molecular circuits with scal-
able single-cell RNA profiling of pooled genetic screens. Cell 2016; 167:1853–
1866.e17.
 34. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data 
with or without a reference genome. BMC Bioinformatics 2011; 12:323.
 35. Li B, Gould J, Yang Y, et al. Cumulus provides cloud-based data analysis for large-
scale single-cell and single-nucleus RNA-seq. Nat Methods 2020; 17:793–8.
 36. Sun Z, Chen L, Xin H, et al. A Bayesian mixture model for clustering droplet-
based single-cell transcriptomic data from population studies. Nat Commun 
2019; 10:1649.
 37. Asp M, Bergenstråhle J, Lundeberg J. Spatially resolved transcriptomes-next gen-
eration tools for tissue exploration. Bioessays 2020; 42:e1900221.
 38. Montoro DT, Haber AL, Biton M, et al. A revised airway epithelial hierarchy in-
cludes CFTR-expressing ionocytes. Nature 2018; 560:319–24.
 39. Reyes M, Filbin MR, Bhattacharyya RP, et al. An immune-cell signature of bacte-






/ofid/article/8/11/ofab483/6375269 by 81392966 user on 07 D
ecem
ber 2021
The Future of Infectious Diseases • OFID • 11
 40. Jarvis JN, Casazza JP, Stone HH, et al. The phenotype of the cryptococcus-specific 
CD4+ memory T-cell response is associated with disease severity and outcome in 
HIV-associated cryptococcal meningitis. J Infect Dis 2013; 207:1817–28.
 41. Linyu L, Ali Abuderman AW, Muzaheed, et al. Modulation of host immune 
status by cryptococcus co-infection during HIV-1 pathogenesis and its impact on 
CD+4 cell and cytokines environment. Microb Pathog 2020; 139:103864.
 42. Tugume L, Rhein J, Hullsiek KH, et al; COAT and ASTRO-CM teams. HIV-
associated cryptococcal meningitis occurring at relatively higher CD4 counts. J 
Infect Dis 2019; 219:877–83.
 43. Camargo JF, Bhimji A, Kumar D, et al. Impaired T cell responsiveness to inter-
leukin-6 in hematological patients with invasive aspergillosis. PLoS One 2015; 
10:e0123171.
 44. Liu F, Fan X, Auclair S, et al. Sequential dysfunction and progressive depletion of 
candida albicans-specific CD4 T cell response in HIV-1 infection. PLoS Pathog 
2016; 12:e1005663.
 45. García-Gil A, Lopez-Bailon LU, Ortiz-Navarrete V. Beyond the antibody: B cells 
as a target for bacterial infection. J Leukoc Biol 2019; 105:905–13.
 46. Hurwitz JL. B cells, viruses, and the SARS-CoV-2/COVID-19 pandemic of 2020. 
Viral Immunol 2020; 33:251–2.
 47. Zargaran FN, Akya A, Rezaeian S, et al. B cell epitopes of four fimbriae antigens of 
Klebsiella pneumoniae: a comprehensive in silico study for vaccine development. 
Int J Pept Res Ther 2020: doi:10.1007/s10989-020-10134-3.
 48. Perrett KP, John TM, Jin C, et al. Long-term persistence of immunity and B-cell 
memory following Haemophilus influenzae type B conjugate vaccination in early 
childhood and response to booster. Clin Infect Dis 2014; 58:949–59.
 49. Stoeckius M, Hafemeister C, Stephenson W, et al. Simultaneous epitope and tran-
scriptome measurement in single cells. Nat Methods 2017; 14:865–8.
 50. Ward RA, Thompson GR, Villani A-C, et al. The known unknowns of the im-
mune response to Coccidioides. J Fungi 2021; 7:377.
 51. Wang F, Flanagan J, Su N, et al. RNAscope: a novel in situ RNA analysis platform 
for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2012; 14:22–9.
 52. Goltsev Y, Samusik N, Kennedy-Darling J, et al. Deep profiling of mouse splenic 
architecture with CODEX multiplexed imaging. Cell 2018; 174:968–81.e15.
 53. Maskarinec SA, Johnson MD, Perfect JR. Genetic susceptibility to fungal infec-
tions: what is in the genes? Curr Clin Microbiol Rep 2016; 3:81–91.
 54. Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. 
Nat Rev Genet 2019; 20:109–27.
 55. Rodríguez-Ubreva J, Ballestar E. Chromatin immunoprecipitation. Methods Mol 
Biol 2014; 1094:309–18.
 56. Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. ATAC-seq: a method for assaying 
chromatin accessibility genome-wide. Curr Protoc Mol Biol 2015; 109:21.29.1–9.
 57. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts 
HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482–5.
 58. Rasmussen TA, Tolstrup M, Brinkmann CR, et al. Panobinostat, a histone 
deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on 
suppressive antiretroviral therapy: a phase ½, single group, clinical trial. Lancet 
HIV 2014; 1:e13–21.
 59. Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity 
and its role in health and disease. Nat Rev Immunol 2020; 20:375–88.
 60. Arts RJ, Novakovic B, Ter Horst R, et al. Glutaminolysis and fumarate accumu-
lation integrate immunometabolic and epigenetic programs in trained immunity. 
Cell Metab 2016; 24:807–19.
 61. Bekkering S, Arts RJW, Novakovic B, et al. Metabolic induction of trained immu-
nity through the mevalonate pathway. Cell 2018; 172:135–46.e9.
 62. Cheng SC, Quintin J, Cramer RA, et al. mTOR- and HIF-1α-mediated aerobic 
glycolysis as metabolic basis for trained immunity. Science 2014; 345:1250684.
 63. Zhang E, Chai JC, Deik AA, et al. Plasma lipidomic profiles and risk of diabetes: 
2 prospective cohorts of HIV-infected and HIV-uninfected individuals. J Clin 
Endocrinol Metab 2021; 106:999–1010.
 64. Guasch-Ferre M, Hu FB, Ruiz-Canela M, et al. Plasma metabolites from cho-
line pathway and risk of cardiovascular disease in the PREDIMED (Prevention 
With Mediterranean Diet) study. J Am Heart Assoc 2017; 6. doi:10.1161/
JAHA.117.006524.
 65. Lloyd-Price J, Arze C, Ananthakrishnan AN, et al; IBDMDB Investigators. Multi-
omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 
2019; 569:655–62.
 66. Mayers JR, Wu C, Clish CB, et al. Elevation of circulating branched-chain amino 
acids is an early event in human pancreatic adenocarcinoma development. Nat 
Med 2014; 20:1193–8.
 67. Paynter NP, Balasubramanian R, Giulianini F, et al. Metabolic predictors of inci-
dent coronary heart disease in women. Circulation 2018; 137:841–53.
 68. Rhee EP, Waikar SS, Rebholz CM, et al.; CKD Biomarkers Consortium. Variability 
of two metabolomic platforms in CKD. Clin J Am Soc Nephrol 2019; 14:40–8.
 69. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of devel-
oping diabetes. Nat Med 2011; 17:448–53.
 70. Zeleznik OA, Eliassen AH, Kraft P, et al. A prospective analysis of circulating 
plasma metabolites associated with ovarian cancer risk. Cancer Res 2020; 
80:1357–67.
 71. Sindelar M, Stancliffe E, Schwaiger-Haber M, et al. Longitudinal metabolomics 
of human plasma reveals prognostic markers of COVID-19 disease severity. Cell 
Rep Med 2021; 2:100369.
 72. Markley JL, Brüschweiler R, Edison AS, et al. The future of NMR-based metabol-
omics. Curr Opin Biotechnol 2017; 43:34–40.
 73. Zhou B, Xiao JF, Tuli L, Ressom HW. LC-MS-based metabolomics. Mol Biosyst 
2012; 8:470–81.
 74. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quies-
cence. Immunity 2013; 38:633–43.
 75. Pellon A, Sadeghi Nasab SD, Moyes DL. New insights in Candida albicans innate 
immunity at the mucosa: toxins, epithelium, metabolism, and beyond. Front Cell 
Infect Microbiol 2020; 10:81.
 76. Traven A, Naderer T. Central metabolic interactions of immune cells and mi-
crobes: prospects for defeating infections. EMBO Rep 2019; 20:e47995.
 77. Domínguez-Andrés J, Arts RJW, Ter Horst R, et al. Rewiring monocyte glucose 
metabolism via C-type lectin signaling protects against disseminated candidiasis. 
PLoS Pathog 2017; 13:e1006632.
 78. Ochando J, Fayad ZA, Madsen JC, et al. Trained immunity in organ transplanta-
tion. Am J Transplant 2020; 20:10–8.
 79. Braza MS, van Leent MMT, Lameijer M, et al. Inhibiting inflammation with mye-
loid cell-specific nanobiologics promotes organ transplant acceptance. Immunity 
2018; 49:819–828.e6.
 80. Blaise BJ, Gouel-Chéron A, Floccard B, et al. Metabolic phenotyping of trauma-
tized patients reveals a susceptibility to sepsis. Anal Chem 2013; 85:10850–5.
 81. Dessì A, Liori B, Caboni P, et al. Monitoring neonatal fungal infection with me-
tabolomics. J Matern Fetal Neonatal Med 2014; 27 (Suppl 2):34–8.
 82. Candia J, Cheung F, Kotliarov Y, et al. Assessment of variability in the SOMAscan 
assay. Sci Rep 2017; 7:14248.
 83. DeBoer EM, Wagner BD, Popler J, et al. Novel application of aptamer proteomic 
analysis in cystic fibrosis bronchoalveolar lavage fluid. Proteomics Clin Appl 
2019; 13:e1800085.
 84. Aghaeepour N, Lehallier B, Baca Q, et al. A proteomic clock of human pregnancy. 
Am J Obstet Gynecol 2018; 218:347.e1–e14.
 85. Feyaerts D, Hedou J, Gillard J, et al. Integrated plasma proteomic and single-cell 
immune signaling network signatures demarcate mild, moderate, and severe 
COVID-19 [preprint]. bioRxiv 2021. doi:10.1101/2021.02.09.430269.
 86. Ghaemi MS, DiGiulio DB, Contrepois K, et al. Multiomics modeling of the 
immunome, transcriptome, microbiome, proteome and metabolome adaptations 
during human pregnancy. Bioinformatics 2019; 35:95–103.
 87. Bendall SC, Simonds EF, Qiu P, et al. Single-cell mass cytometry of differential 
immune and drug responses across a human hematopoietic continuum. Science 
2011; 332:687–96.
 88. Joshi RN, Binai NA, Marabita F, et al. Phosphoproteomics reveals regulatory 
T cell-mediated DEF6 dephosphorylation that affects cytokine expression in 
human conventional T cells. Front Immunol 2017; 8:1163.
 89. Sjoelund V, Smelkinson M, Nita-Lazar A. Phosphoproteome profiling of the mac-
rophage response to different toll-like receptor ligands identifies differences in 
global phosphorylation dynamics. J Proteome Res 2014; 13:5185–97.
 90. Leigh JE, McNulty KM, Fidel PL Jr. Characterization of the immune status of 
CD8+ T cells in oral lesions of human immunodeficiency virus-infected persons 
with oropharyngeal Candidiasis. Clin Vaccine Immunol 2006; 13:678–83.
 91. Suram S, Silveira LJ, Mahaffey S, et al. Cytosolic phospholipase A(2)α and 
eicosanoids regulate expression of genes in macrophages involved in host defense 
and inflammation. PLoS One 2013; 8:e69002.
 92. Terayama Y, Matsuura T, Ozaki K. Induction of severe chronic hyperplastic can-
didiasis in rat by opportunistic infection of C. albicans through combination of 
diabetes and intermittent prednisolone administration. Toxicol Pathol 2017; 
45:745–55.
 93. Won EJ, Choi JH, Cho YN, et al. Biomarkers for discrimination between latent 
tuberculosis infection and active tuberculosis disease. J Infect 2017; 74:281–93.
 94. Gómez-Escobar LG, Hoffman KL, Choi JJ, et al. Cytokine signatures of end organ 
injury in COVID-19. Sci Rep 2021; 11:12606.
 95. Beardsley J, Hoang NLT, Kibengo FM, et al. Do intracerebral cytokine responses 
explain the harmful effects of dexamethasone in human immunodeficiency 
virus-associated cryptococcal meningitis? Clin Infect Dis 2019; 68:1494–501.
 96. Akilimali NA, Chang CC, Muema DM, et al. Plasma but not cerebrospinal fluid 
interleukin 7 and interleukin 5 levels pre-antiretroviral therapy commencement 
predict cryptococcosis-associated immune reconstitution inflammatory syn-
drome. Clin Infect Dis 2017; 65:1551–9.
 97. Ahmad S, Milan MDC, Hansson O, et al. CDH6 and HAGH protein levels in 







/ofid/article/8/11/ofab483/6375269 by 81392966 user on 07 D
ecem
ber 2021
12 • OFID • Ward et al
 98. Ngo D, Sinha S, Shen D, et al. Aptamer-based proteomic profiling reveals novel 
candidate biomarkers and pathways in cardiovascular disease. Circulation 2016; 
134:270–85.
 99. Penn-Nicholson A, Hraha T, Thompson EG, et al; ACS and GC6–74 cohort study 
groups. Discovery and validation of a prognostic proteomic signature for tuber-
culosis progression: a prospective cohort study. PLoS Med 2019; 16:e1002781.
 100. Dong L, Watson J, Cao S, et al. Aptamer based proteomic pilot study reveals a 
urine signature indicative of pediatric urinary tract infections. PLoS One 2020; 
15:e0235328.
 101. Filbin MR, Mehta A, Schneider AM, et al. Longitudinal proteomic analysis of 
plasma from patients with severe COVID-19 reveal patient survival-associated 
signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med 
2021; 2:100287. 
 102. Jehan F, Sazawal S, Baqui AH, et al; Alliance for Maternal and Newborn Health 
Improvement, the Global Alliance to Prevent Prematurity and Stillbirth, and the 
Prematurity Research Center at Stanford University. Multiomics characterization 
of preterm birth in low- and middle-income countries. JAMA Netw Open 2020; 
3:e2029655.
 103. Culos A, Tsai AS, Stanley N, et al. Integration of mechanistic immunological 
knowledge into a machine learning pipeline improves predictions. Nat Mach 
Intell 2020; 2:619–28.
 104. Aghaeepour N, Kin C, Ganio EA, et al. Deep immune profiling of an arginine-
enriched nutritional intervention in patients undergoing surgery. J Immunol 
2017; 199:2171–80.
 105. Schüssler-Fiorenza Rose SM, Contrepois K, Moneghetti KJ, et al. A longitudinal 
big data approach for precision health. Nat Med 2019; 25:792–804.
 106. Stelzer IA, Ghaemi MS, Han X, et al. Integrated trajectories of the maternal me-
tabolome, proteome, and immunome predict labor onset. Sci Transl Med 2021; 
13:e1002781.
 107. Baek B, Lee H. Prediction of survival and recurrence in patients with pancreatic 
cancer by integrating multi-omics data. Sci Rep 2020; 10:18951.
 108. Ding H, Sharpnack M, Wang C, et al. Integrative cancer patient stratification via 
subspace merging. Bioinformatics 2019; 35:1653–9.
 109. Gallivan KA, Srivastava A, Xiuwen L, Dooren PV. Efficient algorithms for 
inferences on Grassmann manifolds. IEEE Workshop on Statistical Signal 
Processing, 2003 (pp. 315–318). IEEE. Available at https://ieeexplore.ieee.org/
document/1289408.
 110. National Institute of Allergy and Infectious Diseases. Human immunology 
project consortium (HIPC). Available at: https://www.niaid.nih.gov/research/
human-immunology-project-consortium. Accessed 6 July 2021.
 111. European Commission. Horizon 2020. Available at: https://ec.europa.eu/pro-






/ofid/article/8/11/ofab483/6375269 by 81392966 user on 07 D
ecem
ber 2021
